Page 16 of 16 — 378 published developments, newest first.
Niagen Bioscience has doubled its share buyback program authorization to $20 million, signaling management's conviction in its business strength amid a perceived public market undervaluation.
Read analysisA preclinical study published in GeroScience demonstrates that d-galactose-induced accelerated aging causes sex-specific cardiovascular pathologies in mice, where heme oxygenase-1 induction selectively rescues male systolic dysfunction while endogenous HO-1 activity remains critical for female cardiac preservation.
Read analysisAn analysis of 742 mothers demonstrates that low maternal plasma folate and lack of prenatal multivitamin use are significantly associated with accelerated biological aging at delivery, highlighting the role of one-carbon nutrition in modulating epigenetic clocks.
Read analysisA newly characterized doxorubicin-induced model of pancreatic β-cell senescence links impaired mitochondrial and insulin granule clearance to altered stimulus-secretion coupling, providing a novel research platform for evaluating metabolic rejuvenation therapies.
Read analysisResearchers found that the antidepressant escitalopram accelerates biological aging in model organisms and human cells by disrupting the conserved IIS/autophagy pathway, suggesting potential safety risks with long-term use.
Read analysisA neuroimaging study of 12,284 postmenopausal females using deep neural networks demonstrated that longer endogenous hormone exposure—indicated by later menopause onset and more births—predicts younger-appearing brains, highlighting the role of sex-specific endocrine pathways in neurological aging.
Read analysisA nationwide survey of 3,034 participants in Singapore established that while 55.5% of the population is interested in attending Healthy Longevity Medicine clinics, only 41.3% can accurately define healthspan, demonstrating a major consumer education gap in the preventative medicine sector.
Read analysisA newly registered clinical trial, CALM-AF-AI, will investigate a combination genetic approach pairing AAV-Follistatin with an angiogenesis-inducing VEGF plasmid to address age-related muscle loss.
Read analysisA newly registered clinical study on ClinicalTrials.gov aims to track changes in biological age using the LinAge2 clinical clock within a real-world medical weight loss setting.
Read analysisA GeroScience narrative review outlines how companion animal cohabitation acts as a modifiable lifestyle factor that may mitigate cognitive aging by modulating neurovascular, neuroimmune, and neuroendocrine pathways.
Read analysisA collaborative review published in Nature Aging consolidates three decades of mammalian research on dietary restriction, detailing key cellular pathways and validating candidate pharmacological mimetics to improve healthspan.
Read analysisA study in Nature Aging demonstrates that turquoise killifish undergo rapid, spontaneous immune system aging and genome instability within 10 weeks, with the senolytic fisetin showing potential to restore aged immune cell function in vitro.
Read analysisNiagen Bioscience has completed the all-cash sale of its ChromaDex Reference Standards business to LGC, streamlining its operations to focus resources exclusively on NAD+ science and product growth.
Read analysisA prospective cohort study published in GeroScience demonstrates that circulating endotrophin, a collagen type VI-derived peptide, correlates with inflammaging and frailty, and independently predicts long-term all-cause mortality in older adults.
Read analysisA genomic study of Italian centenarians published in GeroScience reports that individuals with a higher ancestral connection to post-Ice Age Western hunter-gatherers have a 38% higher probability of reaching age 100, highlighting the role of ancient evolutionary variants in modern cellular resilience.
Read analysisThe longevity sector in 2025 was defined by the first FDA approval of a mitochondria-targeted therapy, growing economic arguments for healthspan-focused healthcare, and state-level legislative expansions of experimental medicine access.
Read analysisDeciduous Therapeutics has emerged from stealth with $6.5 million in early funding to develop therapies that leverage the natural immune system to clear senescent cells.
Read analysisThe registration of the 'STOP-Sepsis' trial marks an expansion of senolytic therapeutic evaluation into acute systemic inflammatory conditions, shifting the clinical focus of cellular senescence away from purely chronic age-related diseases.
Read analysis